Kosten, T.R., and Biegel, D. (2002). Therapeutic vaccines for substance dependence. Expert Review of Vaccines, 1(3), 363-371.

Kosten, T.R., and Kleber, H.D. (1984). Strategies to improve compliance with narcotic antagonists. America Journal of Drug and Alcohol Abuse, 10(2), 249-266.

Kosten, T.R., and O’Connor, P.G. (2003). Current concepts—management of drug withdrawal. New England Journal of Medicine, 348(18), 1786-1795.

Kosten, T.R., Kreek, M.J., Ragunath, J., and Kleber, H.D. (1986). Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biological Psychiatry, 21(2), 217-220.

Kosten, T.R., Rosen, M., Bond, J., Settles, M., Roberts, J.S., Shields, J., Jack, L., and Fox, B. (2002). Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine, 20(7-8), 1196-1204.

Kranzler, H.R. (1995). The pharmacology of alcohol abuse. New York: Springer-Verlag.

Kranzler, H.R. (2000). Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol and Alcoholism, 35(6), 537-547.

Kranzler, H.R., and Van Kirk, J. (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcoholism, Clinical and Experimental Research, 25(9), 1335-1341.

Kranzler, H.R., Modesto-Lowe, V., and Nuwayser, E.S. (1998). Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcoholism, Clinical and Experimental Research, 22(5), 1074-1079.

Kranzler, H.R., Armeli, S., Tennen, H., Blomqvist, O., Oncken, C., Petry, N., and Feinn, R. (2003). Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology, 23(3), 294-304.

Lifshitz, M., Gavrilov, V., and Gorodischer, R. (2001). Off-label and unlicensed use of antidotes in paediatric patients. European Journal of Clinical Pharmacology, 56(11), 839-841.

McIntyre, J., Conroy, S., Avery, A., Corns, H., and Choonara, I. (2000). Unlicensed and off label prescribing of drugs in general practice. Archives of Disease in Childhood, 83(6), 498-501.

Miro, O., Nogue, S., Espinosa, G., To-Figueras, J., and Sanchez, M. (2002). Trends in illicit drug emergencies: The emerging role of gamma-hydroxybutyrate. Journal of Toxicology—Clinical Toxicology, 40(2), 129-135.

Morgan, C., and Kosten, T.R. (1990). Potential toxicity of high dose naltrexone in patients with appetitive disorders. In L. Ried (Ed.), Opioids, bulimia, and alcohol abuse and alcoholism (pp. 261-274). New York: Springer-Verlag.

Nasser, S.M., and Ewan, P.W. (2001). Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. British Medical Journal (Clinical Research Edition), 322(7302), 1589-1591.

National Institute on Drug Abuse (1998). National survey results on drug use from Monitoring the Future survey. Rockville, MD: National Institute on Drug Abuse.

O’Malley, S.S., Jaffe, A.J., Chang, G., Schottenfeld, R.S., Meyer, R.E., and Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry, 49(11), 894-898.

Oncken, C.A., and Kranzler, H.R. (2003). Pharmacotherapies to enhance smoking cessation during pregnancy. Drug and Alcohol Review, 22(2), 191-202.

Oncken, C.A., Pbert, L., Ockene, J.K., Zapka, J., and Stoddard, A. (2000). Nicotine replacement prescription practices of obstetric and pediatric clinicians. Obstetetrics and Gynecology, 96(2), 261-265.

Owens, S.M. (1997). Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. NIDA Research Monograph, 173, 259-272.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement